EMA Defends PRIME's Early Entry Advantage For SMEs
This article was originally published in SRA
Executive Summary
The European Medicines Agency has defended the early entry advantage that small and medium-sized enterprises (SMEs) will have under agency proposals for the new priority medicines scheme that is due for launch early next year1.